Posts Tagged ‘CSIRO’

Dyesol Announces JV Agreement With CSIRO

Wednesday, May 5th, 2010

Dyesol (DYE), a world leader in the commercialisation of dye solar cell (DSC) technology and CSIRO expect to finalise the documents shortly that define a collaboration which has the objective to develop higher performing dyes in a two year project funded by CSIRO’s Australian Growth Partnership (AGP) programme. The details will be announced to the market upon execution.

Under the proposed terms of the collaboration, Dyesol will project manage a specialised team of experienced scientists from CSIRO to work with the Company on an agreed development program leveraging Dyesol’s deep knowledge of ruthenium based dyes and CSIRO’s extensive modelling and research capability. The program will target the creation of new intellectual property (IP) that the Company expects will further reinforce its market leadership position in the DSC photovoltaic market. Under the proposed terms, Dyesol can exclusively access the project IP.

Ruthenium based dyes, known as organo-metallic dyes, are at the core of DSC technology. DSC requires the deposition of nano-particulate titania, ruthenium dyes and an electrolyte, sandwiched between suitable substrates, capturing light and, through an electrochemical process, converting it into energy. DSC is particularly suited to building integrated photovoltaic (BIPV) applications offering an energy solution to the built environment which is the largest consumer of electrical power globally.

Dyesol Australia’s Chief Executive Officer, Ross MacDiarmid said: “This project is a further example of the effectiveness of Dyesol’s commercialisation strategy in which partnerships with global companies such as CORUS (Tata Steel) to develop metal based products and the collaboration with Pilkington NA to develop glass-based products, is complemented by the programs with technology leaders like Merck and the CSIRO to develop valuable IP around higher performing materials. We look forward to partnering and consider this another milestone in the inexorable progress of DSC to the market place.”

The arrangements being finalised, involve the purchase of a Dyesol laboratory solution by CSIRO, a direct investment into Dyesol via the AGP program and in-kind contributions from both CSIRO’s Energy Transformed Flagship and Dyesol itself.   Should the program outcomes be achieved, the terms of the financing facility provides Dyesol with flexibility in respect to its preferred repayment options including the issue of equity to CSIRO and/or royalty stream participation.

Dyesol believes that once executed, this world-class partnership will add to those already in place, offering it an exceptional opportunity to leverage the R&D capability of its collaborators with the application development experience of its commercial partners to support the business model that will deliver DSC products to the world market.

www.dyesol.com

Post to Twitter

Circadian JV Agreement With CSIRO

Tuesday, December 8th, 2009

Dr Steve Morton, CSIRO Group Executive, announced today a new long term, strategic alliance between Circadian Technologies (CIR) and CSIRO to work together on the ongoing research and development of Circadian’s VEGF technology to develop promising new potential treatments for cancer. The alliance is part of the CSIRO’s program to assist and facilitate development of new technologies with Australian biotech companies and will see CSIRO and Circadian collaborate in activities to aid the development of Circadian’s novel, biologics-based treatments for cancer and other serious diseases. Circadian will provide funding and access to its technology and lead drug candidates (molecules), while CSIRO will provide access to its world class biological production infrastructure, process development capability and internal research expertise. The announcement comes on the opening day of the new Protein Production Facility at CSIRO funded by both the Federal and State Victorian Governments. This Facility forms a significant part of CSIRO’s infrastructure capability that is accessible to the Australian Biotech industry. Specifically, the CSIRO and Circadian alliance will focus on the development of improved production systems for Circadian’s molecules, molecular modelling, assay development, testing of future drug candidates as well as other projects which may be mutually agreed by the parties.

Robert Klupacs, CEO of Circadian said: “We are extremely excited by this collaboration. Having access to CSIRO’s world class infrastructure and research expertise will greatly assist us in bringing our molecules to the clinic. Circadian has a strong position in this area of potential therapeutics for cancer and we applaud the vision of the CSIRO to work closely with Australian companies such as ours, encouraging us to continue to develop important new treatments and innovations which may one day have the potential to impact on many lives globally.” Dr Steve Morton CSIRO Group Executive said: ”CSIRO is very pleased to be working with Circadian, an Australian biotech company, to advance its product development pipeline. This alliance highlights that there is already industry uptake of our new Protein Production Facility and research capability. CSIRO is all about partnering with and delivering to Australian industry and our new Facility will be a key enabler for the biotech industry. “

Circadian (CIR) is a biologics drug developer utilising the significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF) C and D that it has accumulated in its unlisted wholly owned subsidiary Vegenics. The applications for the VEGF technology, which functions in regulating blood supply, are substantial and broad. Circadian’s internal product development programs are focussed on novel anti-cancer therapeutics for large unmet needs. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems (a wholly owned subsidiary of Eli Lilly & Company ). ImClone Systems is currently developing an antibody-based drug targeting VEGFR-3 for the treatment of solid tumours.   CSIRO is Australia’s national science agency and one of the largest and most diverse research agencies in the world. CSIRO’s research in materials and manufacturing will continue to assist Australia grow a high-value, globally competitive manufacturing sector. We undertake research with partners in key manufacturing sectors including biotechnology to advance their product development pipelines.

www.circadian.com.au

Post to Twitter

Avexa Joint Venture with CSIRO For Hepatitis C Research

Wednesday, July 15th, 2009

Avexa Limited (AVX) today announced that the Commonwealth Scientific and Industrial Research Organisation (CSIRO) will invest up to A$2M into Avexa’s hepatitis C virus (HCV) program through the CSIRO’s Australian Growth Partnerships (AGP) program.

“HCV is a serious condition particularly for those patients who are chronically infected. As one of the largest and most diverse scientific research organisations in the world, we are excited to work with the CSIRO to better understand this terrible disease,” said Dr Julian Chick, Chief Executive Officer of Avexa.

The agreement will enable Avexa and the CSIRO to combine skill sets and abilities to discover new medicines for Hepatitis C. Hepatitis C is an infectious disease affecting over 180 million people globally and is a leading cause of chronic liver disease resulting in liver inflammation, cirrhosis and liver cancer. The Avexa/CSIRO collaboration will initially focus on the identification of small molecule inhibitors targeting the NS5B RNA polymerase which is essential to this replication process. Under the terms of the agreement, CSIRO could either share in the upside of the program if it is successful, or convert its $2M investment into equity once the program is complete which is expected to be in two years. In some circumstances Avexa may elect, or be required, to repay the investment.

The Commonwealth Scientific and Industrial Research Organisation, CSIRO, is Australia’s premier research organisation which provides scientific solutions to industry, governments and communities around the world. Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of small molecules for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including apricitabine (ATC), its HIV integrase program, its HCV polymerase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company’s lead program, ATC, is an anti-HIV drug that has successfully completed the 16 week dose determination step of its worldwide Phase III trial.

www.csiro.au/AGP

www.avexa.com.au

Post to Twitter